DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer
NASDAQ: ACB | TSX: ACB

Aurora Cannabis Inc.

Medical Cannabis Leader + Strategic Pivot to Global Markets

Market Cap: ~CAD $271M | Price: CAD $4.78 | 52-week: CAD $4.50–$9.33
ACB Chart - Price CAD $4.78
Chart: 1-year daily bars | Current Price: CAD $4.78 | 52-week range: CAD $4.50–$9.33 Data as of March 4, 2026
NEXT MAJOR CATALYST
FY2026 Full-Year Results + International Expansion
Q3 FY2026 completed (Dec 31, 2025). Expected: Q4 FY2026 results (fiscal year ends March 31, 2026); TD Cowen Health Care Conference presentation (March 2, 2026); plant propagation divestiture completion; continued German/Poland medical expansion.

? Executive Summary

Aurora Cannabis is a Canadian medical cannabis company undergoing a strategic transformation. In Q3 FY2026 (ended December 31, 2025), Aurora reported estimated $94.2M CAD in net revenue (+7% YoY), with record medical cannabis revenue of $76.2M CAD (+12% YoY). The company is pivoting aggressively toward high-margin global medical markets (especially Germany, Poland, Australia, UK), exiting lower-margin consumer segments in Canada, and divesting its plant propagation business.

Key Financial Strengths: Aurora holds estimated $154.4M CAD in total liquidity (cash + short-term investments), with $56.4M CAD in cash and equivalents, and zero cannabis-related debt. On an adjusted basis, the company generated positive free cash flow of $15.5M CAD in Q3 and reported adjusted EBITDA of $18.5M CAD with adjusted net income of $7.2M CAD. However, on a GAAP basis, Q3 showed a net loss of $1.9M CAD, and the 9-month year-to-date net loss was $74.8M CAD (including $31.9M impairment on Australian cannabis and plant propagation assets). Importantly, adjusted gross margins in the medical cannabis segment remain robust at 69%, demonstrating pricing power in international markets.

Strategic Shift & Catalysts: Aurora filed a estimated $100M CAD at-the-market (ATM) equity program on February 4, 2026, to fund cultivation capacity expansion and selective M&A. Management guided full-year FY2026 (ending March 31, 2026) global medical cannabis revenue of $269M–$281M CAD, with adjusted EBITDA growth of 5–10%. The company is consolidating its position as Canada’s largest global medical cannabis exporter and a leader in key European and Australian markets.

Stock Performance & Valuation: ACB traded at estimated CAD $4.78 on March 4, 2026, down from a 52-week high of $9.33 but stable vs. Q3 earnings (Feb 4, 2026). With estimated market cap of ~CAD $271M and profitable operations (adjusted net income positive), the company offers a less volatile cannabis exposure compared to peers focused on volatile consumer markets.

Sources (Executive Summary – SEC Primary): SEC Form 6-K Filing: Aurora Cannabis Q3 FY2026 Form 6-K (Feb 4, 2026) | SEC EDGAR | Q3 FY2026 earnings call (Feb 4, 2026), PRNewswire press releases, Yahoo Finance, Motley Fool earnings transcript, TipRanks.

? Snapshot & Key Financials

Market Cap & Shares

~CAD $271M (as of Mar 4, 2026) | ~56.3M shares outstanding | NASDAQ: ACB | TSX: ACB

Cash Position (Q3 FY2026)

$56.4M CAD cash & equivalents | $154.4M CAD total liquidity (cash + ST investments) | $61.8M CAD Bevo non-recourse debt (current)

Profitability & Results

Net Loss Q3: $1.9M CAD | Adjusted EBITDA: $18.5M CAD | Adjusted Net Income: $7.2M CAD | Free Cash Flow: $15.5M CAD

Core Financials (Q3 FY2026, ended Dec 31, 2025)

  • Net Revenue: $94.2M CAD (+7% YoY) | Global medical cannabis: record $76.2M CAD (+12%)
  • Gross Margin: 62% consolidated; medical cannabis segment: 69% (robust)
  • International Revenue Growth: +17% YoY, led by Germany and new Poland launches
  • Consumer Cannabis Revenue: $5.2M CAD (-48% YoY) – strategic exit ongoing
  • Plant Propagation Margin: 16% (down from 40%, due to restructuring)
  • Free Cash Flow: $15.5M CAD (down from $27.4M prior year due to working capital timing)
  • Cash Runway: Estimated 15+ quarters at current burn (no urgency)
Sources (Snapshot – SEC Primary): SEC Form 6-K Filing: Aurora Cannabis Q3 FY2026 Form 6-K (Feb 4, 2026) | SEC EDGAR | Q3 FY2026 earnings call (Feb 4, 2026), PRNewswire official release, Motley Fool transcript, TipRanks, MacroTrends market cap data.

? Company Overview & Strategic Transformation

Background: From Consumer-Heavy to Medical-First

Aurora Cannabis was founded in 2013 and is headquartered in Edmonton, Alberta, Canada. The company trades on both NASDAQ (ACB) and Toronto Venture Exchange (ACB) and operates two segments: Canadian Cannabis (medical + consumer) and Plant Propagation (vegetables, floral plants).

Historically, Aurora pursued a diversified cannabis strategy including both consumer and medical channels, plus non-cannabis businesses. However, over the past 18–24 months, management under CEO Miguel Martin has executed a decisive pivot toward high-margin global medical cannabis markets. This shift is grounded in observable market dynamics: medical cannabis commands premium pricing (69% adjusted gross margins) compared to consumer cannabis, and international markets (Germany, Australia, Poland, UK) offer both scale and regulatory tailwinds.

Current Strategic Focus (Medical-First, Global)

Aurora’s current strategy prioritizes:

  • Global Medical Cannabis Expansion: Focus on Germany (largest market), Poland (growing), Australia, UK, and emerging EU markets. Record Q3 medical revenue of $76.2M CAD (+12%) demonstrates momentum.
  • Exit from Consumer Cannabis in Canada: Management explicitly stated openness to “fully exiting consumer cannabis in Canada” if strategically beneficial. Consumer revenue declined 48% in Q3 ($5.2M CAD) as the company reallocates high-quality flower to higher-margin international medical markets.
  • Divestiture of Plant Propagation: Aurora is divesting its controlling interest in the plant propagation segment (vegetables, floral plants) to streamline operations and redeploy capital to medical cannabis.
  • Manufacturing & Quality Leadership: ~90% of Aurora’s annual manufacturing capacity is produced in EU-GMP and TGA-GMP-certified facilities (Canada, Germany, Australia), positioning the company as a premium supplier to regulated medical markets.
  • Science & IP-Driven Positioning: Aurora has developed proprietary genetics and plant varieties (e.g., powdery mildew-resistant strains). Recent patents granted in Australia and IP development underway.
Sources (Company Overview): Q3 FY2026 earnings call (Feb 4, 2026), CEO Miguel Martin statements, PRNewswire press releases (Feb 3–11, 2026), company investor relations (ir.auroramj.com).

? Product Portfolio & Brand Strategy

Global Medical Cannabis Brands

Aurora operates a diversified brand portfolio tailored to regional markets. Medical brands include:

  • Pedanios, Bidiol, IndiMed: European medical brands with strong regulatory credentials and physician trust.
  • MedReleaf: Canadian medical brand; Aurora acquired MedReleaf in 2018 and integrated it into the global medical portfolio.
  • Daily Special: Recently expanded into German and Australian markets; positioned as an affordable, accessible medical option.
  • CanniMed, WMMC: Legacy Canadian medical brands retained for domestic medical channel.

Consumer Brands (Strategic Exit Underway)

  • San Rafael ’71, Greybeard, Drift, Being, Tasty’s: Adult-use consumer brands; being systematically exited from lower-margin Canadian consumer markets.

Recent Product Launches & Expansion

  • Australia/New Zealand (Feb 11, 2026): Aurora launched four premium cannabis resin cartridges in Australia (Chemango Kush, Cosmic Cream, Lunar Express, Soul Train Haze) and three THC flower products in New Zealand (Big Wave, Night Ride, Half Moon) using proprietary genetics and certified manufacturing.
  • Poland (Q3 2026): Continued new product launches drove +17% international medical revenue growth, with Poland cited as a key growth driver alongside Germany.
  • Powdery Mildew-Resistant Genetics: Aurora advanced powdery mildew-resistant cannabis genetics into production trials (announced Dec 24, 2025), addressing a key cultivation challenge in some markets.

Intellectual Property & Patents

  • Australian Patent Grants (Jan 2026): IP Australia granted 18 patent claims for secreted Klotho (s-KL) isoform compositions and uses (in partnership with Universitat Autonoma de Barcelona). Claims cover muscle-cell-specific promoter linked to s-KL gene for motor impairment treatment and delivery systems (AAV, non-viral vectors).
  • Plant Variety Rights (Jan 14, 2026): Aurora granted community plant variety rights from the EU for proprietary cannabis strains, protecting Aurora’s genetic library in European markets.
Sources (Portfolio/Products): PRNewswire announcements (Jan 14, 18, Feb 3, 11, 2026), Q3 earnings call, investor relations communications.

? Financial Position & Capital Strategy

Balance Sheet Strength

Aurora’s balance sheet is among the strongest in the global cannabis industry. Q3 FY2026 showed estimated $154M CAD in cash and short-term investments with zero cannabis-related debt. This positions Aurora favorably against peers, most of which carry significant debt or are cash-constrained.

Management explicitly highlighted: “Our balance sheet remains one of the strongest in the global cannabis industry, and our cannabis operations are completely debt-free.”

Profitability & Cash Generation

Unlike most cannabis peers, Aurora has demonstrated strong adjusted profitability metrics, though GAAP net income reflects one-time items and fair value adjustments:

  • Q3 Net Loss (GAAP): $1.9M CAD loss (reflects inventory provisions, fair value adjustments on biological assets, and restructuring costs).
  • 9-Month YTD Net Loss: $74.8M CAD loss (includes $31.9M impairment on goodwill/intangibles in Australian cannabis and plant propagation segments).
  • Adjusted EBITDA: $18.5M CAD in Q3 (reflects operational profitability before D&A and one-time items).
  • Adjusted Net Income: $7.2M CAD in Q3 (profitable on an adjusted basis, excluding non-cash and one-time items).
  • Free Cash Flow: $15.5M CAD in Q3 (positive FCF generation).
  • Profitability Trend: Adjusted EBITDA of $18.5M CAD in Q3 FY2026 (vs. $19.4M CAD in Q3 FY2025); slight decrease due to plant propagation margin compression and increased European headcount, but medical cannabis segment remains highly profitable at 69% margins.

Capital Strategy & ATM Program

On February 4, 2026, Aurora filed a prospectus supplement establishing an estimated $100M CAD at-the-market (ATM) equity program. The ATM allows Aurora to issue up to $100M CAD of common shares at prevailing market prices to fund:

  • Increased cultivation capacity expansion (particularly in high-margin international markets).
  • Strategic, accretive M&A pursuits (management emphasized “accretive” uses only).

Dilution Risk: At the current stock price of CAD $4.78, issuing shares under the ATM would dilute existing shareholders. However, management has emphasized a disciplined approach to capital deployment, with focus on high-return, strategic uses.

FY2026 Guidance (Fiscal Year Ending March 31, 2026)

Management provided the following outlook for full-year FY2026:

  • Global Medical Cannabis Net Revenue: $269M–$281M CAD (up YoY, driven by 10–15% growth in global medical cannabis segment).
  • Adjusted EBITDA Growth: 5–10% YoY.
  • Plant Propagation Revenue: Expected to follow seasonal trends (65–75% earned in H1 of calendar year).
Sources (Financial Situation – SEC Primary): SEC Form 6-K Filing: Aurora Cannabis Q3 FY2026 Form 6-K (Feb 4, 2026) | SEC EDGAR | Q3 FY2026 earnings call (Feb 4, 2026), PRNewswire official release, Motley Fool earnings transcript, CFO Simona King commentary.

⏳ Catalysts & Timeline (FY2026–2027)

  • February 4, 2026 Q3 FY2026 Earnings Release & ATM Filing: Aurora announced strong Q3 results (revenue $94.2M CAD, adjusted EBITDA $18.5M CAD, free cash flow $15.5M CAD). Filed $100M CAD ATM equity program.
  • February 11–18, 2026 Australia/New Zealand Expansion & Nasdaq Bell Ringing: Aurora announced expanded medical cannabis portfolio launches in Australia and New Zealand (Feb 11). CEO Miguel Martin rang the Nasdaq closing bell on Feb 18 to highlight global medical-first strategy.
  • March 2, 2026 TD Cowen 46th Annual Health Care Conference: CFO Simona King to participate in fireside chat and investor meetings to discuss international leadership and manufacturing trends.
  • End of March 2026 Q4 FY2026 Results (Fiscal Year End, March 31, 2026): Full-year FY2026 results expected to be released in late April/early May 2026. Key metrics: Global medical cannabis revenue ($269M–$281M CAD guidance), adjusted EBITDA growth (5–10%).
  • Q1 FY2027 Onwards (April 2026+) Plant Propagation Divestiture Completion: Aurora to complete divestiture of plant propagation segment. Continued International Expansion: Additional launches in European and Australian markets. Analyst Rating Updates: Recent analyst initiations at Canaccord (Jan 21, 2026: Buy, target C$10; lowered to C$9 on Feb 5) suggest ongoing investor interest.
Sources (Catalysts/Timeline): PRNewswire press releases (Feb 3–18, 2026), Q3 earnings call (Feb 4, 2026), investor relations calendar, Canaccord analyst reports (TipRanks).

⚠️ Principal Risk Factors

  • Bevo Covenant Breach & Refinancing Risk (CRITICAL): Bevo Farms breached both fixed charge coverage and non-financial covenants on its credit facility at December 31, 2025, causing C$61.8M of loans and borrowings to be classified as current liabilities. The company is seeking waivers or amended credit agreements from its lender. A high-cost 17% unsecured creditor agreement of C$5.0M underscores funding pressure at Bevo. Aurora’s planned preferred-share restructuring aims to deconsolidate Bevo and treat it as discontinued operations (post-closing), which would remove this liability from Aurora’s consolidated balance sheet but requires lender consent and execution.
    • Medical cannabis regulations vary widely by jurisdiction. Unfavorable regulatory changes in Germany, Poland, Australia, or UK could reduce market access or reimbursement rates. Conversely, legalization in additional markets could open opportunities.
  • Commodity Price & Pricing Pressure: Aurora faces price competition in certain markets (e.g., Germany consumer segment noted as “value” competitive). Oversupply in mature markets could pressure margins. However, Aurora’s focus on premium medical channel (69% margins) mitigates this risk vs. consumer-focused peers.
  • Currency Risk: Aurora reports in CAD but earns significant revenue in EUR and AUD. Currency weakness (CAD strength) would reduce reported earnings; CAD weakness would support earnings translation.
  • Plant Propagation Divestiture Execution: Aurora is divesting plant propagation (margin compressed to 16%). Execution risk exists if buyer/deal terms deteriorate. However, strategic focus on medical cannabis is clear.
  • Consumer Cannabis Exit Risk: Aurora is exiting lower-margin Canadian consumer cannabis. If demand shifts unexpectedly toward consumer, Aurora could lose market share. However, management’s conviction in medical-first thesis appears strong.
  • Dilution from ATM Program: $100M CAD ATM program could dilute shareholders if fully utilized at depressed stock prices. However, “accretive” discipline and strong cash position ($154M CAD) suggest limited immediate dilution risk.
  • M&A Integration Risk: Aurora may pursue selective M&A. Integration of acquisitions carries execution risk (talent retention, culture, financial performance).
  • Supply Chain & Manufacturing Risk: ~90% of capacity is in EU-GMP/TGA-GMP-certified facilities. Regulatory issues, quality problems, or production disruptions could impact revenue and margins.
  • Key Person Risk: CEO Miguel Martin and CFO Simona King are instrumental to strategic execution. Loss of key management would create uncertainty.
Sources (Risks – SEC Primary): SEC Form 6-K Filing: Aurora Cannabis Q3 FY2026 Form 6-K (Feb 4, 2026) | SEC EDGAR | Q3 earnings call (management commentary on market dynamics), investor relations materials, prior financial filings, cannabis industry analyst reports, regulatory monitoring (Health Canada, EU, TGA).

? Potential Scenarios (2026–2028)

Bull Case: “Medical Cannabis Consolidation Leader”

Aurora successfully executes its medical-first, global strategy. Q4 FY2026 results beat guidance on international medical revenue. German market continues robust 15%+ growth; Polish market scales faster than expected. Aurora completes plant propagation divestiture and redeployment of capital yields accretive M&A (e.g., acquiring smaller European medical cannabis companies). Margins expand to 70%+ on consolidated medical cannabis segment. Stock re-rates to C$7–10 range based on validated market position and positive cash generation story.

Probability: Moderate (~25–35%). Requires flawless execution on international expansion and M&A integration.

Base Case: “Steady Medical Expansion, Mild Margin Pressure”

Aurora delivers FY2026 guidance on revenue ($269M–$281M CAD) but EBITDA growth comes in at lower end of 5–10% range. International medical revenue grows 10–12% as expected, but German market faces incremental competitive pricing pressure (noted in Q3 call). Consumer cannabis exit proceeds smoothly; plant propagation divestiture occurs mid-2026. Free cash flow remains positive but declines slightly as capex ramps for international expansion. Stock drifts in C$4–6 range, held back by ongoing dilution concerns and slower-than-expected margin expansion.

Probability: High (~50–60%). Most likely given mature market dynamics and execution complexity.

Bear Case: “Regulatory Headwinds & Execution Stumbles”

German government tightens cannabis reimbursement or introduces price controls; Polish market stalls on regulatory delays. Aurora’s FY2026 results miss guidance on medical cannabis revenue; EBITDA flattens or declines. Plant propagation divestiture encounters buyer challenges; asset sits on balance sheet longer than expected. Costs to exit Canadian consumer markets exceed expectations, pressuring cash flow. Aurora forced into larger-than-expected equity dilution via ATM program. Stock trades in C$2.50–4.00 range, reflecting investor skepticism on international execution and delisting risk if stock remains sub-C$3 for 30+ consecutive trading days.

Probability: Low–Moderate (~15–25%). Reflects regulatory and execution risks in international markets.

Catalyst-Specific Wildcards

Major M&A Announced: Aurora acquires a large European or Australian medical cannabis company (e.g., German player with established medical distribution). Deal could be transformative if accretive; stock upside 2–3x.

German Cannabis Legalization Acceleration: If German government expedites recreational legalization (currently in discussion), demand could spike. Aurora’s German medical presence positions it well for recreational entry.

Sources (Scenarios): Q3 FY2026 earnings call, management guidance, regulatory monitoring (Health Canada, EU cannabis policy), historical cannabis industry M&A patterns, competitive analysis vs. Tilray, Canopy Growth, other global players.

? Market Sentiment & Analyst Coverage

Important Disclaimer: Sentiment data from stock forums (Reddit, Stocktwits, X/Twitter) and analyst reports reflect speculative trading narratives and professional research, respectively. These are NOT investment recommendations and carry bias.

Analyst Coverage (Recent Initiations)

  • Canaccord Genuity (Jan 21, 2026 – Buy Initiation): Initiated coverage with a Buy rating and estimated C$10 CAD price target, citing Aurora’s medical-first strategy and international opportunity.
  • Canaccord Genuity (Feb 5, 2026 – Target Reduction): Lowered price target from C$10 to C$9 CAD, possibly reflecting near-term margin pressure in plant propagation segment or macro concerns. Maintained Buy rating.
  • Average Analyst Target (Investing.com): Estimated 12-month average analyst target: C$7.62 CAD, with high estimate of C$10 and low of C$5. Consensus appears modestly bullish (implied 59% upside from C$4.78 current price to C$7.62 target).

Retail Sentiment (Reddit, Stocktwits)

  • Bullish Themes: Medical cannabis focus is seen as less volatile than consumer plays; Q3 earnings beat on profitability and free cash flow; international growth narrative resonates with investors seeking growth in maturing markets.
  • Bearish Themes: Cannabis sector underperformance vs. broader market; dilution concerns (ATM program); slow-moving regulatory approvals in Europe; competitive pressure from larger peers (Tilray, Canopy).
  • Overall Retail Sentiment: Mixed-to-cautiously-bullish. ACB is not a “meme stock” and attracts fundamental-focused retail investors. Volume on earnings days (Feb 4) was elevated, but average daily volume is moderate (~2–3M shares).

Short Interest & Technical Setup

  • Short Interest: Cannabis sector attracts short sellers due to dilution and margin pressure narratives. ACB short interest not explicitly disclosed in search results, but likely moderate given regulatory environment.
  • Technical Setup: ACB trading near mid-range of 52-week ($4.50–$9.33). Analyst target of C$7.62 implies resistance overhead; support may be found near C$4.50 level.
Sources (Sentiment): TipRanks analyst reports, Investing.com consensus, Canaccord research, Reddit r/stocks and r/cannabis, Stocktwits ACB room, financial news aggregators.

? Valuation & Comparables

Aurora trades at an estimated market cap of ~CAD $271M with demonstrated profitability (adjusted net income $7.2M CAD in Q3; free cash flow $15.5M CAD). This positions ACB favorably vs. unprofitable cannabis peers.

Valuation Metrics (Estimated)

  • Market Cap: ~CAD $271M
  • TTM Adjusted Net Income: ~CAD $28.8M (extrapolated from Q3 $7.2M)
  • Implied P/E (Adjusted): ~9.4x (CAD $271M / CAD $28.8M)
  • EV/EBITDA (Estimated): ~13x (assuming ~CAD $154M cash net of liability)
  • Price-to-Sales (Trailing): ~0.7x (estimated CAD $377M+ annual revenue / CAD $271M market cap)

Comparable Companies

Aurora is comparable to large-cap Canadian cannabis producers: Tilray (TLRY), Canopy Growth (CGC). However, Aurora’s medical-first positioning and profitability distinguish it from peers focused on volatile consumer markets.

  • Tilray Brands (TLRY): ~$2.5B USD market cap; larger scale but more diversified (including hemp, beer). Less focused on medical.
  • Canopy Growth (CGC): ~$1.8B CAD market cap; historically focused on consumer; recently pivoted to medical. Larger than Aurora but similar strategic direction.
  • Aurora vs. Peers: Aurora’s CAD $271M market cap is smaller than TLRY/CGC, which could reflect execution risk or market skepticism. However, Aurora’s focus on profitable medical cannabis and strong balance sheet ($154M cash) positions it as a potential consolidation target or acquisition currency.

Valuation Assessment

At ~9.4x estimated adjusted P/E and ~0.7x price-to-sales, Aurora appears reasonably valued for a profitable, growth-oriented cannabis company. The Canaccord analyst target of C$7.62 (vs. current C$4.78) implies ~59% upside, which would be justified if:

  • International medical revenue accelerates to 15%+ growth.
  • Margins expand toward 70%+ on consolidated medical segment.
  • Plant propagation divestiture yields capital redeployment into higher-margin assets.

At current levels, ACB offers a less-volatile cannabis exposure for investors seeking profitability and international upside.

Sources (Valuation): Market cap from Investing.com, MacroTrends; financial metrics from Q3 earnings call; Canaccord analyst report (Jan 21, 2026); comparable company data from Yahoo Finance, TipRanks, FactSet.

? Bottom Line & Key Takeaways

  • Medical Cannabis Consolidator: Aurora is executing a high-conviction pivot toward global medical cannabis markets (Germany, Poland, Australia, UK) and away from volatile Canadian consumer cannabis. Medical segment achieved record revenue of $76.2M CAD (+12%) in Q3 with 69% margins.
  • Adjusted Profitability & FCF-Positive (Adjusted Basis): Aurora is profitable on an adjusted basis (adjusted EBITDA $18.5M CAD, adjusted net income $7.2M CAD, FCF $15.5M CAD). However, on a GAAP basis, Q3 reported a net loss of $1.9M CAD, and the 9-month YTD net loss was $74.8M CAD (driven by inventory provisions, fair value adjustments, and $31.9M impairment on Australian and plant propagation assets). Balance sheet shows $154.4M CAD in total liquidity (cash + ST investments) and $56.4M CAD in cash equivalents; $61.8M CAD Bevo non-recourse debt classified as current pending covenant waiver/refinancing.
  • Strategic Catalysts Ahead: Q4 FY2026 results (expected April 2026), plant propagation divestiture, continued international expansion, potential M&A utilizing $100M CAD ATM program.
  • Valuation: Trading at ~9.4x estimated adjusted P/E and ~0.7x price-to-sales; modest premium to unprofitable peers but discount to larger-cap TLRY/CGC. Analyst target C$7.62 (vs. current C$4.78) implies ~59% upside if strategy executes.
  • Risks: Regulatory headwinds in key markets (Germany, EU), pricing pressure, currency risk, execution on plant propagation exit and M&A, shareholder dilution from ATM program.
  • Investment Profile: ACB is suitable for investors seeking exposure to global medical cannabis growth with lower volatility than consumer-focused peers. Profitability, cash generation, and international upside appeal to value and growth investors. Not recommended for high-risk, speculative traders seeking binary catalysts.
Sources (Bottom Line): Comprehensive synthesis: Q3 FY2026 earnings call, PRNewswire press releases, analyst reports (Canaccord), market data (Investing.com, MacroTrends), comparable company analysis.

? Additional Resources & Related Coverage

These resources provide detailed financial statements, management commentary, and regulatory updates to support your independent analysis of Aurora Cannabis.

Disclaimer (ENGLISH): This report is provided exclusively for informational and educational purposes. It does NOT constitute financial advice, investment recommendation, or solicitation to the public for savings. The information is sourced from what are believed to be reliable sources (SEC/SEDAR filings, official press releases, earnings call transcripts, reputable financial news outlets), but no guarantee is given regarding accuracy or completeness. Scenarios, examples, and interpretations are hypothetical and subject to change without notice.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a publicly traded cannabis company operating in regulated markets. Cannabis remains a federally controlled substance in the United States, and regulations vary by jurisdiction. Investors are strongly encouraged to conduct their own due diligence, review all official SEC/SEDAR filings, consult with a qualified financial advisor, and understand local cannabis regulations before making any investment decision.

Past performance and analyst estimates do NOT guarantee future results. All investments carry risk of loss, including total loss of capital.

Independent report on Aurora Cannabis Inc. (ACB) – updated March 4, 2026 – no buy or sell recommendation.

? Sintesi Esecutiva

Aurora Cannabis è un’azienda canadese di cannabis medica in fase di trasformazione strategica. Nel Q3 FY2026 (terminato il 31 dicembre 2025), Aurora ha riportato ricavi netti stimati di CAD $94,2M (+7% YoY), con ricavi medici record di CAD $76,2M (+12% YoY). L’azienda sta ruotando aggressivamente verso mercati medici globali ad alto margine (specialmente Germania, Polonia, Australia, UK), uscendo da segmenti consumer a basso margine in Canada e cedendo il business di propagazione delle piante.

Punti di forza finanziari chiave: Aurora detiene stimati CAD $154M in cassa con zero debiti correlati alla cannabis—uno dei bilanci più solidi dell’industria. L’azienda ha generato flusso di cassa libero positivo di CAD $15,5M nel Q3 e ha riportato EBITDA rettificato di CAD $18,5M con utile netto rettificato di CAD $7,2M. Soprattutto, i margini lordi rettificati nel segmento cannabis medica rimangono robusti al 69%, dimostrando potere di prezzo nei mercati internazionali.

Rotazione strategica & Catalyst: Aurora ha depositato un programma at-the-market (ATM) stimato di CAD $100M il 4 febbraio 2026, per finanziare l’espansione della capacità di coltivazione e M&A selettivo. Il management ha guidato il FY2026 completo (terminato il 31 marzo 2026) ricavi medici cannabis globali di CAD $269M–$281M, con crescita EBITDA rettificato di 5–10%. L’azienda sta consolidando la sua posizione come principale esportatore di cannabis medica del Canada e leader nei principali mercati europei e australiani.

Performance del titolo & Valutazione: ACB è scambiato a stimati CAD $4,78 il 4 marzo 2026, in calo dal massimo 52 settimane di $9,33 ma stabile vs. Q3 earnings (4 febbraio 2026). Con market cap stimato di ~CAD $271M e operazioni redditizie (utile netto rettificato positivo), l’azienda offre un’esposizione al cannabis meno volatile rispetto ai peer focalizzati su mercati consumer volatili.

Fonti (sintesi esecutiva): Q3 FY2026 earnings call (4 febbraio 2026), comunicati stampa PRNewswire, Yahoo Finance, Motley Fool earnings transcript, TipRanks.

? Snapshot & Dati Finanziari Chiave

Market Cap & Azioni

~CAD $271M (al 4 marzo 2026) | ~56,3M azioni in circolazione | NASDAQ: ACB | TSX: ACB

Posizione di Cassa (Q3 FY2026)

$154M CAD cassa + investimenti a breve termine | Zero debiti correlati a cannabis | Bilancio solido

Redditività & FCF

EBITDA Rettificato: $18,5M CAD | Utile Netto Rettificato: $7,2M CAD | Flusso di Cassa Libero: $15,5M CAD (positivo!)

Dati Finanziari di Base (Q3 FY2026, terminato 31 dic 2025)

  • Ricavi Netti: CAD $94,2M (+7% YoY) | Cannabis medico globale: record CAD $76,2M (+12%)
  • Margine Lordo: 62% consolidato; segmento cannabis medica: 69% (robusto)
  • Crescita Ricavi Internazionali: +17% YoY, guidata da Germania e nuovi lanci in Polonia
  • Ricavi Cannabis Consumer: CAD $5,2M (-48% YoY) – uscita strategica in corso
  • Margine Propagazione Piante: 16% (giù dal 40%, dovuto a ristrutturazione)
  • Flusso di Cassa Libero: CAD $15,5M (giù dai CAD $27,4M anno precedente per timing del working capital)
  • Runway di Cassa: Stimato 15+ trimestri al burn rate attuale (nessuna urgenza)
Fonti (snapshot – SEC Primary): SEC Form 6-K Filing: Aurora Cannabis Q3 FY2026 Form 6-K (4 febbraio 2026) | SEC EDGAR | Q3 FY2026 earnings call (4 febbraio 2026), comunicato ufficiale PRNewswire, transcript Motley Fool, TipRanks, dati MacroTrends market cap.

? Panoramica Aziendale & Trasformazione Strategica

Sfondo: Da Consumer-Heavy a Medical-First

Aurora Cannabis è stata fondata nel 2013 e ha sede a Edmonton, Alberta, Canada. L’azienda opera in due segmenti: Cannabis Canadese (medico + consumer) e Propagazione Piante (verdure, piante ornamentali). Storicamente, Aurora ha perseguito una strategia diversificata includendo canali consumer e medico, più business non-cannabis. Tuttavia, negli ultimi 18–24 mesi, il management sotto il CEO Miguel Martin ha eseguito una rotazione decisiva verso mercati medici globali ad alto margine. Questo shift è fondato sulla dinamica di mercato osservata: la cannabis medica comanda prezzi premium (margini rettificati lordi 69%) rispetto al cannabis consumer, e i mercati internazionali (Germania, Australia, Polonia, UK) offrono scala e tailwind normativi.

Focus Strategico Attuale (Medical-First, Globale)

La strategia attuale di Aurora prioritizza:

  • Espansione Cannabis Medica Globale: Focus su Germania (mercato più grande), Polonia (crescente), Australia, UK e mercati UE emergenti. Il record medico Q3 di $76,2M CAD (+12%) dimostra momentum.
  • Uscita da Consumer Cannabis in Canada: Il management ha esplicitamente dichiarato apertura a “uscire completamente da consumer cannabis in Canada” se strategicamente vantaggioso. I ricavi consumer sono calati 48% nel Q3 ($5,2M CAD) mentre l’azienda reallocates fiore di qualità alta a mercati internazionali medici ad alto margine.
  • Cessione di Propagazione Piante: Aurora sta cedendo la sua partecipazione di controllo nel segmento propagazione piante (verdure, piante ornamentali) per razionalizzare operazioni e redeployare capitale verso cannabis medica.
  • Leadership Manifatturiero & Qualità: ~90% della capacità manifatturiera annuale di Aurora è prodotta in strutture EU-GMP e TGA-GMP-certificate (Canada, Germania, Australia), posizionando l’azienda come fornitore premium a mercati medici regolamentati.
  • Posizionamento IP-Driven & Scientifico: Aurora ha sviluppato genetiche proprietarie e varietà di piante (es. ceppi resistenti alla polvere bianca). Brevetti recenti e sviluppo IP in corso.
Fonti (panoramica aziendale): Q3 FY2026 earnings call (4 febbraio 2026), dichiarazioni CEO Miguel Martin, comunicati stampa PRNewswire (3–18 febbraio 2026), relazioni investor (ir.auroramj.com).

? Portfolio Prodotti & Strategia Brand

Brand Cannabis Medica Globale

Aurora opera un portfolio diversificato di brand tailored ai mercati regionali. I brand medici includono:

  • Pedanios, Bidiol, IndiMed: Brand medici europei con forte credibilità normativa e fiducia medica.
  • MedReleaf: Brand medico canadese; Aurora ha acquisito MedReleaf nel 2018 e l’ha integrato nel portfolio medico globale.
  • Daily Special: Recentemente espanso nei mercati tedesco e australiano; posizionato come opzione medica accessibile.
  • CanniMed, WMMC: Brand medici canadesi legacy mantenuti per canale medico domestico.

Brand Consumer (Uscita Strategica in Corso)

  • San Rafael ’71, Greybeard, Drift, Being, Tasty’s: Brand consumer adult-use; sistematicamente in uscita da mercati consumer canadesi a basso margine.

Lanci Prodotto Recenti & Espansione

  • Australia/Nuova Zelanda (11 febbraio 2026): Aurora ha lanciato quattro cartucce premium cannabis resin in Australia (Chemango Kush, Cosmic Cream, Lunar Express, Soul Train Haze) e tre prodotti fiore THC in Nuova Zelanda (Big Wave, Night Ride, Half Moon) usando genetiche proprietarie e manufacturing certificato.
  • Polonia (Q3 2026): Continui lanci di nuovi prodotti hanno guidato crescita medica internazionale +17%, con Polonia citata come driver chiave insieme alla Germania.
  • Genetiche Resistenti a Polvere Bianca: Aurora ha avanzato genetiche cannabis resistenti a polvere bianca in trial produttivi (annunciato 24 dicembre 2025), indirizzando una sfida chiave di coltivazione in alcuni mercati.

Proprietà Intellettuale & Brevetti

  • Concessioni Brevetto Australiane (gennaio 2026): IP Australia ha concesso 18 reclami brevettabili per composizioni isoformi Klotho segretate (s-KL) e usi (in partnership con Universitat Autonoma de Barcelona). I reclami coprono promotori cell-muscolari-specifici linked a gene s-KL per trattamento deficienza motoria e sistemi di consegna (AAV, vettori non-virali).
  • Diritti Varietà Piante (14 gennaio 2026): Aurora ha ricevuto diritti comunità varietà piante dall’UE per ceppi cannabis proprietari, proteggendo la libreria genetica di Aurora nei mercati europei.
Fonti (portfolio/prodotti): Annunci PRNewswire (14, 18 gennaio, 3, 11 febbraio 2026), Q3 earnings call, comunicazioni investor relations.

? Posizione Finanziaria & Strategia di Capitale

Solidità del Bilancio

Il bilancio di Aurora è tra i più solidi dell’industria cannabis globale. Q3 FY2026 ha mostrato stimati $154,4M CAD in cassa e investimenti a breve termine con zero debiti correlati a cannabis. Questo posiziona Aurora favorevolmente contro peer, la maggior parte dei quali porta debito significativo o è cash-constrained.

Il management ha esplicitamente sottolineato: “Il nostro bilancio rimane uno dei più solidi dell’industria cannabis globale, e le nostre operazioni cannabis sono completamente debt-free.”

Redditività & Generazione di Cassa

A differenza della maggior parte dei peer cannabis, Aurora ha dimostrato strong metriche di redditività adjusted, sebbene l’utile netto GAAP rifletta one-time items e fair value adjustments:

  • Perdita Netta Q3 (GAAP): Perdita di $1,9M CAD (riflette disposizioni inventory, fair value adjustments su biological assets, e costi ristrutturazione).
  • Perdita Netta YTD 9-mesi: Perdita di $74,8M CAD (include impairment $31,9M su goodwill/intangibili in cannabis australiana e segmenti propagazione piante).
  • EBITDA Rettificato: $18,5M CAD nel Q3 (riflette redditività operativa before D&A e one-time items).
  • Utile Netto Rettificato: $7,2M CAD nel Q3 (redditizio su base rettificata, escludendo non-cash e one-time items).
  • Flusso di Cassa Libero: $15,5M CAD nel Q3 (generazione FCF positiva).
  • Trend Redditività: EBITDA rettificato di $18,5M CAD nel Q3 FY2026 (vs. $19,4M CAD nel Q3 FY2025); diminuzione leggera dovuta a compressione margine propagazione piante e headcount europeo aumentato, ma il segmento cannabis medica rimane altamente redditizio al 69% di margini.

Strategia di Capitale & Programma ATM

Il 4 febbraio 2026, Aurora ha depositato un supplemento prospettus stabilendo un programma at-the-market (ATM) stimato di $100M CAD. L’ATM consente ad Aurora di emettere fino a $100M CAD di azioni ordinarie a prezzi di mercato prevalenti per finanziare:

  • Espansione di capacità di coltivazione aumentata (particolarmente nei mercati internazionali ad alto margine).
  • Perseguimenti M&A strategici, accretive (il management ha enfatizzato usi “accretive” solamente).

Rischio Diluizione: Al prezzo azionario attuale di CAD $4,78, l’emissione di azioni sotto l’ATM diluerebbe gli azionisti esistenti. Tuttavia, il management ha enfatizzato un approccio disciplinato al deployment di capitale, con focus su usi high-return, strategici.

Guidance FY2026 (Anno Fiscale Terminato 31 marzo 2026)

Il management ha fornito il seguente outlook per l’anno fiscale completo FY2026:

  • Ricavo Netto Cannabis Medica Globale: $269M–$281M CAD (up YoY, guidato da crescita 10–15% nel segmento cannabis medica globale).
  • Crescita EBITDA Rettificato: 5–10% YoY.
  • Ricavo Propagazione Piante: Expected to follow stagional trends (65–75% earned in H1 of calendar year).
Fonti (situazione finanziaria – SEC Primary): SEC Form 6-K Filing: Aurora Cannabis Q3 FY2026 Form 6-K (4 febbraio 2026) | SEC EDGAR | Q3 FY2026 earnings call (4 febbraio 2026), comunicato ufficiale PRNewswire, transcript Motley Fool, commenti CFO Simona King.

⏳ Catalyst & Timeline (FY2026–2027)

  • 4 febbraio 2026 Rilascio Utili Q3 FY2026 & Filing ATM: Aurora ha annunciato strong risultati Q3 (ricavo $94,2M CAD, EBITDA rettificato $18,5M CAD, flusso cassa libero $15,5M CAD). Ha depositato programma equity ATM $100M CAD.
  • 11–18 febbraio 2026 Espansione Australia/Nuova Zelanda & Nasdaq Bell Ringing: Aurora ha annunciato portfolio medico cannabis espanso launches in Australia e Nuova Zelanda (11 febbraio). CEO Miguel Martin ha suonato la campana di chiusura Nasdaq il 18 febbraio per evidenziare strategia global medical-first.
  • 2 marzo 2026 TD Cowen 46th Annual Health Care Conference: CFO Simona King parteciperà in fireside chat e investor meetings per discutere leadership internazionale e manufacturing trends.
  • Fine marzo 2026 Risultati Q4 FY2026 (Fine Anno Fiscale, 31 marzo 2026): Risultati anno fiscale completo FY2026 expected to be released in late April/early May 2026. Key metrics: Ricavo cannabis medica globale ($269M–$281M CAD guidance), crescita EBITDA rettificato (5–10%).
  • Q1 FY2027 Onwards (aprile 2026+) Completamento Cessione Propagazione Piante: Aurora completare la cessione del segmento propagazione piante. Espansione Internazionale Continua: Lanci aggiuntivi in mercati europei e australiani. Aggiornamenti Rating Analisti: Iniziazioni recenti di analisti a Canaccord (21 gennaio 2026: Buy, target C$10; ridotto a C$9 il 5 febbraio) suggeriscono interesse investitore continuo.
Fonti (Catalyst/Timeline): Comunicati stampa PRNewswire (3–18 febbraio 2026), Q3 earnings call (4 febbraio 2026), investor relations calendar, report analisti Canaccord (TipRanks).

⚠️ Fattori di Rischio Principali

  • Rischio Bevo Covenant Breach & Refinancing (CRITICO): Bevo Farms ha violato sia fixed charge coverage che covenant non-finanziario sulla sua credit facility al 31 dicembre 2025, causando C$61,8M di loans e borrowings ad essere classified come current liabilities. L’azienda sta cercando waivers o amended credit agreements dal suo lender. Un unsecured creditor agreement ad alto costo 17% di C$5,0M sottolinea funding pressure a Bevo. La ristrutturazione preferred-share di Aurora aims a de-consolidare Bevo e trattarlo come discontinued operations (post-closing), che rimuoverebbe questa liability dal consolidated balance sheet di Aurora ma richiede lender consent e execution.
  • Rischio Normativo Cannabis (Globale): Le normative cannabis medica variano largamente per giurisdizione. Cambiamenti normativi sfavorevoli in Germania, Polonia, Australia, o UK potrebbero ridurre market access o reimbursement rates. Conversely, legalizzazione in mercati aggiuntivi potrebbe aprire opportunità.
  • Volatilità Prezzo Commodity & Pricing Pressure: Aurora affronta competizione prezzo in certi mercati (es. segmento consumer tedesco notato come competitivo “value”). Oversupply in mercati maturi potrebbe pressurare margini. Tuttavia, focus di Aurora su canale medico premium (margini 69%) mitiga questo rischio vs. peer focalizzati su consumer.
  • Rischio Valuta: Aurora riporta in CAD ma earned ricavi significativi in EUR e AUD. Currency weakness (CAD strength) ridurrebbe earning reported; CAD weakness supporterebbe earnings translation.
  • Rischio Esecuzione Cessione Propagazione Piante: Aurora sta cedendo propagazione piante (margine compresso a 16%). Execution risk esiste se termini buyer/deal deteriorano. Tuttavia, focus strategico su cannabis medica è chiaro.
  • Rischio Uscita Consumer Cannabis: Aurora sta uscendo da cannabis consumer canadese a basso margine. Se domanda shifta inaspettatamente verso consumer, Aurora potrebbe perdere market share. Tuttavia, conviction del management sulla medical-first thesis appare forte.
  • Rischio Diluizione da Programma ATM: Il programma ATM da $100M CAD potrebbe diluire azionisti se pienamente utilizzato a prezzi azionari depressi. Tuttavia, disciplina “accretive” e forte posizione cassa ($154,4M CAD) suggeriscono rischio diluizione limitato near-term.
  • Rischio Integrazione M&A: Aurora può perseguire M&A selettivo. L’integrazione di acquisizioni porta execution risk (talent retention, cultura, performance finanziaria).
  • Rischio Supply Chain & Manufacturing: ~90% di capacità è in strutture EU-GMP/TGA-GMP-certificate. Problemi regolatori, qualità, o disruptions produzione potrebbero impattare ricavo e margini.
  • Rischio Key Person: CEO Miguel Martin e CFO Simona King sono strumentali all’execution strategico. Perdita di management chiave creerebbe uncertainty.
Fonti (rischi – SEC Primary): SEC Form 6-K Filing: Aurora Cannabis Q3 FY2026 Form 6-K (4 febbraio 2026) | SEC EDGAR | Q3 earnings call (management commentary su dinamica di mercato), investor relations materials, prior financial filings, report analisti industria cannabis, monitoring normativo (Health Canada, EU, TGA).

? Potenziali Scenari (2026–2028)

Bull Case: “Medical Cannabis Consolidation Leader”

Aurora esegue con successo strategia medical-first, globale. Risultati Q4 FY2026 beat guidance su medical revenue internazionale. Mercato tedesco continua growth robusto 15%+; mercato polacco scala faster than expected. Aurora completa cessione propagazione piante e redeployment di capitale yields accretive M&A (es. acquisisce smaller European medical cannabis companies). Margini expandono a 70%+ su consolidated medical cannabis segment. Stock re-rates a C$7–10 range basato su validated market position e positive cash generation story.

Probabilità: Moderate (~25–35%). Richiede flawless execution su international expansion e M&A integration.

Base Case: “Steady Medical Expansion, Mild Margin Pressure”

Aurora delivere FY2026 guidance su revenue ($269M–$281M CAD) ma EBITDA growth viene al lower end del range 5–10%. International medical revenue cresce 10–12% as expected, ma mercato tedesco affronta incremental competitive pricing pressure (notato nella Q3 call). Consumer cannabis exit procede smoothly; plant propagation divestiture occurs mid-2026. Free cash flow rimane positive ma declines leggermente while capex ramps per international expansion. Stock drifts in C$4–6 range, held back da ongoing dilution concerns e slower-than-expected margin expansion.

Probabilità: High (~50–60%). Most likely dato mature market dynamics e execution complexity.

Bear Case: “Regulatory Headwinds & Execution Stumbles”

Governo tedesco tightens cannabis reimbursement o introduce price controls; mercato polacco stalls su regulatory delays. Risultati FY2026 di Aurora miss guidance su medical cannabis revenue; EBITDA flattens o declines. Plant propagation divestiture encounters buyer challenges; asset sits on balance sheet longer than expected. Costi ad exit mercati consumer canadesi exceed expectations, pressurando cash flow. Aurora forced in larger-than-expected equity dilution via ATM program. Stock trades in C$2.50–4.00 range, riflettendo investor skepticism su international execution e delisting risk se stock rimane sub-C$3 per 30+ consecutive trading days.

Probabilità: Low–Moderate (~15–25%). Riflette regulatory e execution risks in international markets.

Catalyst-Specific Wildcards

Major M&A Announced: Aurora acquisisce large European o Australian medical cannabis company (es. German player con established medical distribution). Deal potrebbe essere transformative se accretive; stock upside 2–3x.

German Cannabis Legalization Acceleration: Se governo tedesco expedites recreational legalization (currently in discussion), domanda potrebbe spike. Aurora’s German medical presence posiziona well per recreational entry.

? Market Sentiment & Analyst Coverage

Important Disclaimer: Sentiment data da stock forums (Reddit, Stocktwits, X/Twitter) e analyst reports riflettono speculative trading narratives e professional research, rispettivamente. Questi SONO NON investment recommendations e carry bias.

Analyst Coverage (Recent Initiations)

  • Canaccord Genuity (21 gennaio 2026 – Buy Initiation): Initiated coverage con Buy rating e estimated C$10 CAD price target, citando Aurora’s medical-first strategy e international opportunity.
  • Canaccord Genuity (5 febbraio 2026 – Target Reduction): Lowered price target da C$10 a C$9 CAD, possibly riflettendo near-term margin pressure su plant propagation segment o macro concerns. Maintained Buy rating.
  • Average Analyst Target (Investing.com): Estimated 12-month average analyst target: C$7.62 CAD, con high estimate di C$10 e low di C$5. Consensus appare modestly bullish (implied 59% upside da C$4.78 current price a C$7.62 target).

Retail Sentiment (Reddit, Stocktwits)

  • Bullish Themes: Medical cannabis focus è visto come less volatile than consumer plays; Q3 earnings beat su profitability e free cash flow; international growth narrative resonates con investors cercando growth in maturing markets.
  • Bearish Themes: Cannabis sector underperformance vs. broader market; dilution concerns (ATM program); slow-moving regulatory approvals in Europe; competitive pressure da larger peers (Tilray, Canopy).
  • Overall Retail Sentiment: Mixed-to-cautiously-bullish. ACB non è un “meme stock” e attrae fundamental-focused retail investors. Volume su earnings days (Feb 4) era elevated, ma average daily volume è moderate (~2–3M shares).

Short Interest & Technical Setup

  • Short Interest: Cannabis sector attrae short sellers dovuto a dilution e margin pressure narratives. ACB short interest non explicitly disclosed in search results, ma likely moderate dato regulatory environment.
  • Technical Setup: ACB trading near mid-range di 52-week ($4.50–$9.33). Analyst target di C$7.62 implica resistance overhead; support potrebbe trovarsi vicino livello C$4.50.

? Valutazione & Comparabili

Aurora trades ad estimated market cap di ~CAD $271M con demonstrated profitability (adjusted net income $7,2M CAD nel Q3; free cash flow $15,5M CAD). Questo posiziona ACB favorevolmente vs. unprofitable cannabis peers.

Valuation Metrics (Estimated)

  • Market Cap: ~CAD $271M
  • TTM Adjusted Net Income: ~CAD $28,8M (extrapolated da Q3 $7,2M)
  • Implied P/E (Adjusted): ~9.4x (CAD $271M / CAD $28,8M)
  • EV/EBITDA (Estimated): ~13x (assuming ~CAD $154M cash net di liability)
  • Price-to-Sales (Trailing): ~0.7x (estimated CAD $377M+ annual revenue / CAD $271M market cap)

Comparable Companies

Aurora è comparable ai large-cap Canadian cannabis producers: Tilray (TLRY), Canopy Growth (CGC). Tuttavia, Aurora’s medical-first positioning e profitability lo distingue dai peer focalizzati su volatile consumer markets.

  • Tilray Brands (TLRY): ~$2.5B USD market cap; larger scale ma più diversificato (including hemp, beer). Less focused su medical.
  • Canopy Growth (CGC): ~$1.8B CAD market cap; historically focalizzato su consumer; recently pivoted a medical. Larger than Aurora but similar strategic direction.
  • Aurora vs. Peers: Aurora’s CAD $271M market cap è smaller than TLRY/CGC, che potrebbe riflettere execution risk o market skepticism. Tuttavia, Aurora’s focus su profitable medical cannabis e strong balance sheet ($154,4M CAD cash) lo posiziona come potential consolidation target o acquisition currency.

Valuation Assessment

Ad ~9.4x estimated adjusted P/E e ~0.7x price-to-sales, Aurora appare reasonably valued per una profitable, growth-oriented cannabis company. Lo Canaccord analyst target di C$7.62 (vs. current C$4.78) implica ~59% upside, che sarebbe justified se:

  • International medical revenue accelerates a 15%+ growth.
  • Margini expandono verso 70%+ su consolidated medical segment.
  • Plant propagation divestiture yields capital redeployment in higher-margin assets.

A livelli attuali, ACB offre less-volatile cannabis exposure per investors cercando profitability e international upside.

? Bottom Line & Key Takeaways

  • Medical Cannabis Consolidator: Aurora sta eseguendo un high-conviction pivot verso global medical cannabis markets (Germania, Polonia, Australia, UK) e away da volatile Canadian consumer cannabis. Medical segment ha raggiunto record revenue di $76,2M CAD (+12%) in Q3 con 69% margini.
  • Adjusted Profitability & FCF-Positive (Adjusted Basis): Unlike most cannabis peers, Aurora è profitable su base rettificata (EBITDA rettificato $18,5M CAD, adjusted net income $7,2M CAD, FCF $15,5M CAD). Tuttavia, su base GAAP, Q3 ha riportato net loss di $1,9M CAD, e 9-month YTD net loss era $74,8M CAD (guidato da inventory provisions, fair value adjustments, e $31,9M impairment su Australian e plant propagation assets). Balance sheet shows $154,4M CAD in total liquidity (cash + ST investments) e $56,4M CAD in cash equivalents; $61,8M CAD Bevo non-recourse debt classified as current pending covenant waiver/refinancing.
  • Strategic Catalysts Ahead: Q4 FY2026 results (expected April 2026), plant propagation divestiture, continued international expansion, potential M&A utilizing $100M CAD ATM program.
  • Valuation: Trading at ~9.4x estimated adjusted P/E e ~0.7x price-to-sales; modest premium a unprofitable peers ma discount a larger-cap TLRY/CGC. Analyst target C$7.62 (vs. current C$4.78) implica ~59% upside se strategy executes.
  • Rischi: Regulatory headwinds in key markets (Germania, EU), pricing pressure, currency risk, execution su plant propagation exit e M&A, shareholder dilution da ATM program, Bevo covenant breach e refinancing risk.
  • Investment Profile: ACB è suitable per investors cercando exposure a global medical cannabis growth con lower volatility than consumer-focused peers. Profitability, cash generation, e international upside appeal a value e growth investors. Non raccomandato per high-risk, speculative traders cercando binary catalysts.

? Risorse Aggiuntive & Copertura Correlata

Queste risorse forniscono detailed financial statements, management commentary, e regulatory updates a supporto della tua independent analysis di Aurora Cannabis.

Disclaimer (ITALIANO): Questo report è fornito esclusivamente a scopi informativi ed educativi. NON costituisce consulenza finanziaria, raccomandazione di investimento o sollecitazione al pubblico dei risparmi. Le informazioni provengono da fonti ritenute affidabili (filing SEC/SEDAR, comunicati ufficiali, transcript earnings call, outlet di notizie finanziarie autorevoli), ma non è fornita alcuna garanzia riguardante accuratezza o completezza. Scenari, esempi e interpretazioni hanno natura ipotetica e sono soggetti a cambio senza preavviso.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) è una società pubblica di cannabis che opera in mercati regolamentati. Cannabis rimane una sostanza controllata federale negli Stati Uniti e le normative variano per giurisdizione. Gli investitori sono fortemente incoraggiati a condurre la propria due diligence, rivedere tutti i filing SEC/SEDAR ufficiali, consultare un consulente finanziario qualificato e comprendere le normative locali sulla cannabis prima di prendere qualsiasi decisione di investimento.

Le performance passate e le stime degli analisti NON garantiscono risultati futuri. Tutti gli investimenti comportano rischio di perdita, inclusa perdita totale del capitale.

Report indipendente su Aurora Cannabis Inc. (ACB) – aggiornato 4 marzo 2026 – nessuna raccomandazione di acquisto o vendita.

Disclaimer (ITALIANO): Questo report è fornito esclusivamente a scopi informativi ed educativi. NON costituisce consulenza finanziaria, raccomandazione di investimento o sollecitazione al pubblico dei risparmi. Le informazioni provengono da fonti ritenute affidabili (filing SEC/SEDAR, comunicati ufficiali, transcript earnings call, outlet di notizie finanziarie autorevoli), ma non è fornita alcuna garanzia riguardante accuratezza o completezza. Scenari, esempi e interpretazioni hanno natura ipotetica e sono soggetti a cambio senza preavviso.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) è una società pubblica di cannabis che opera in mercati regolamentati. Cannabis rimane una sostanza controllata federale negli Stati Uniti e le normative variano per giurisdizione. Gli investitori sono fortemente incoraggiati a condurre la propria due diligence, rivedere tutti i filing SEC/SEDAR ufficiali, consultare un consulente finanziario qualificato e comprendere le normative locali sulla cannabis prima di prendere qualsiasi decisione di investimento.

Le performance passate e le stime degli analisti NON garantiscono risultati futuri. Tutti gli investimenti comportano rischio di perdita, inclusa perdita totale del capitale.

Report indipendente su Aurora Cannabis Inc. (ACB) – aggiornato 4 marzo 2026 – nessuna raccomandazione di acquisto o vendita.
Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.